Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.11)
# 449
Out of 4,851 analysts
63
Total ratings
53.49%
Success rate
13.49%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $9.34 | -3.64% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $30.44 | +8.41% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $126.55 | +50.14% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $92.40 | +8.23% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $18.75 | +1.33% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $353.32 | +10.38% | 4 | Mar 6, 2025 | |
| TEM Tempus AI | Downgrades: Neutral | $50 → $55 | $62.78 | -12.39% | 3 | Feb 25, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $55 | $47.76 | +15.16% | 1 | Feb 21, 2025 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $160 | $114.94 | +39.20% | 6 | Nov 26, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $650 → $670 | $403.66 | +65.98% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $80 | $70.36 | +13.70% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $5.29 | +278.07% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.16 | - | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,169.67 | +19.69% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $6 | $9.98 | -39.88% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.03 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $37.83 | +137.91% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $193.08 | +39.84% | 4 | Dec 20, 2023 |
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $9.34
Upside: -3.64%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $30.44
Upside: +8.41%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $126.55
Upside: +50.14%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $92.40
Upside: +8.23%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $18.75
Upside: +1.33%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $353.32
Upside: +10.38%
Tempus AI
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $62.78
Upside: -12.39%
Guardant Health
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $47.76
Upside: +15.16%
Agilent Technologies
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $114.94
Upside: +39.20%
Thermo Fisher Scientific
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $403.66
Upside: +65.98%
Aug 12, 2024
Maintains: Overweight
Price Target: $88 → $80
Current: $70.36
Upside: +13.70%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $5.29
Upside: +278.07%
Aug 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.16
Upside: -
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,169.67
Upside: +19.69%
Aug 2, 2024
Maintains: Overweight
Price Target: $5 → $6
Current: $9.98
Upside: -39.88%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.03
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $37.83
Upside: +137.91%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $193.08
Upside: +39.84%